These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 32188412)

  • 41. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
    Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
    Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma.
    Naito T; Udagawa H; Sato J; Horinouchi H; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Ohe Y; Ishii G; Goto K
    J Thorac Oncol; 2019 Oct; 14(10):1818-1827. PubMed ID: 31260834
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.
    Kao C; McNamara M; Alley C; Spector N; Jauhari S; Gupta RT; Zhang T; Zhu J
    Clin Genitourin Cancer; 2019 Jun; 17(3):e672-e677. PubMed ID: 31097390
    [No Abstract]   [Full Text] [Related]  

  • 45. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
    Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
    Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Programmed death-ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and cervical squamous cell carcinoma of HIV-infected and non-infected patients.
    Brito MJ; Sequeira P; Quintas A; Silva I; Silva F; Martins C; Félix A
    Virchows Arch; 2024 Mar; 484(3):507-516. PubMed ID: 37341812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Programmed Cell Death-Ligand-1 expression in Bladder Schistosomal Squamous Cell Carcinoma -
    Madureira AC
    Front Immunol; 2022; 13():955000. PubMed ID: 36148227
    [No Abstract]   [Full Text] [Related]  

  • 50. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.
    Galsky MD; Bajorin DF; Witjes JA; Gschwend JE; Tomita Y; Nasroulah F; Li J; Collette S; Valderrama BP; Grimm MO; Appleman L; Gravis G; Necchi A; Ye D; Stenner F; Wind-Rotolo M; Zhang J; Ünsal-Kaçmaz K
    Eur Urol; 2023 May; 83(5):432-440. PubMed ID: 36868932
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
    Munari E; Rossi G; Zamboni G; Lunardi G; Marconi M; Sommaggio M; Netto GJ; Hoque MO; Brunelli M; Martignoni G; Haffner MC; Moretta F; Pegoraro MC; Cavazza A; Samogin G; Furlan V; Mariotti FR; Vacca P; Moretta L; Bogina G
    Am J Surg Pathol; 2018 Oct; 42(10):1384-1389. PubMed ID: 29901568
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PD-L1 detection using
    Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
    J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
    Dibbern ME; Bullock TN; Jenkins TM; Duska LR; Stoler MH; Mills AM
    Am J Surg Pathol; 2020 Sep; 44(9):1184-1191. PubMed ID: 32496434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
    Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
    Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
    Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.
    Doi T; Piha-Paul SA; Jalal SI; Saraf S; Lunceford J; Koshiji M; Bennouna J
    J Clin Oncol; 2018 Jan; 36(1):61-67. PubMed ID: 29116900
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
    Okamoto I; Sato H; Tsukahara K
    Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.